» Articles » PMID: 38534027

The Shift in the Fatty Acid Composition of the Circulating Lipidome in Alzheimer's Disease

Overview
Specialties Neurology
Psychiatry
Date 2024 Mar 27
PMID 38534027
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Fatty acids (FAs) are the building blocks of complex lipids and signaling compounds; the role of the lipidome fatty acid profile (LFA) in AD progression remains unclear.

Methods: The LFA of plasma and cerebrospinal fluid (CSF) samples from 289 participants (103 AD patients, 92 MCI patients, and 94 controls) was determined by GC-FID. The MCI subjects were followed up for 58 ± 12.5 months.

Results: In controls, CSF has a more neuroprotective LFA than plasma. In CSF, a higher content of docosahexaenoic acid was associated with a reduced risk of MCI-to-AD progression. In plasma, higher oleic acid content was associated with lower risk of AD, MCI, and MCI-to-AD progression, whereas higher levels of vaccenic acid and docosahexaenoic acid were associated with greater risk of AD and MCI, and higher rate of MCI-to-AD progression, respectively.

Discussion: The circulating LFA is involved in the pathogenesis and progression of AD.

Highlights: The lipidome fatty acid profile in CSF and plasma was markedly different. Higher levels of vaccenic acid and lower levels of oleic acid in plasma were associated with greater risk of Alzheimer's disease. In plasma, higher levels of oleic acid were associated with a reduced risk of MCI-to-AD progression. Higher levels of docosahexaenoic acid in CSF were associated with a lower risk of MCI-to-AD progression. Higher levels of docosahexaenoic acid in plasma were associated with a greater rate of MCI-to-AD progression.

Citing Articles

Hyperbaric Oxygen Improves Cognitive Impairment Induced by Hypoxia via Upregulating the Expression of Oleic Acid and MBOAT2 of Mice.

Li Z, Fu J, Jiang K, Gao J, Guo Y, Li C Antioxidants (Basel). 2024; 13(11).

PMID: 39594462 PMC: 11591255. DOI: 10.3390/antiox13111320.


The shift in the fatty acid composition of the circulating lipidome in Alzheimer's disease.

Dakterzada F, Jove M, Cantero J, Mota-Martorell N, Pamplona R, Pinoll-Ripoll G Alzheimers Dement. 2024; 20(5):3322-3333.

PMID: 38534027 PMC: 11095469. DOI: 10.1002/alz.13792.

References
1.
Murakami M . Lipid mediators in life science. Exp Anim. 2011; 60(1):7-20. DOI: 10.1538/expanim.60.7. View

2.
Sahlin C, Pettersson F, Nilsson L, Lannfelt L, Johansson A . Docosahexaenoic acid stimulates non-amyloidogenic APP processing resulting in reduced Abeta levels in cellular models of Alzheimer's disease. Eur J Neurosci. 2007; 26(4):882-9. DOI: 10.1111/j.1460-9568.2007.05719.x. View

3.
Wang Z, Tan L, Liu J, Yu J . The Essential Role of Soluble Aβ Oligomers in Alzheimer's Disease. Mol Neurobiol. 2015; 53(3):1905-1924. DOI: 10.1007/s12035-015-9143-0. View

4.
Caroli A, Prestia A, Galluzzi S, Ferrari C, van der Flier W, Ossenkoppele R . Mild cognitive impairment with suspected nonamyloid pathology (SNAP): Prediction of progression. Neurology. 2015; 84(5):508-15. PMC: 4336071. DOI: 10.1212/WNL.0000000000001209. View

5.
Yassine H, Feng Q, Azizkhanian I, Rawat V, Castor K, Fonteh A . Association of Serum Docosahexaenoic Acid With Cerebral Amyloidosis. JAMA Neurol. 2016; 73(10):1208-1216. DOI: 10.1001/jamaneurol.2016.1924. View